US Patent

US6515117 — C-aryl glucoside SGLT2 inhibitors and method

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2025-10-04 · 1y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating diabetes and related diseases using a specific SGLT2 inhibiting compound.

USPTO Abstract

An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-493 — Farxiga
U-2139 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-2588 —
U-2588 —
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-2588 —
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga

Patent Metadata

Patent number
US6515117
Jurisdiction
US
Classification
Method of Use
Expires
2025-10-04
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.